EPO and myelodysplastic syndrome: In the present trial, HI-E response was defined by strictly applying the IWG 2006 criteria [25], in line with the previous phase 2 PACE-MDS trial of luspatercept and the phase 3 EPOANE trial, the registration trial that led to the approval of epoetin-α in MDS [14, 29].